国产泊沙康唑对生殖器来源念珠菌的体外药物敏感性研究

摘要/Abstract

摘要： 目的了解国产泊沙康唑对生殖器念珠菌病病原菌的体外抑菌活性。方法参照美国临床和实验室标准协会制定的M27-A4方案测定国产泊沙康唑及其他常用抗真菌药物对60株生殖器念珠菌病致病菌的最低抑菌浓度（MIC）值。结果国产泊沙康唑对氟康唑耐药白念珠菌的MIC范围为0.25~0.50 μg/mL，几何均数为0.40 μg/mL，MIC₅₀为0.5 μg/mL，MIC₉₀为0.5 μg/mL；对近平滑念珠菌的MIC范围为0.03~0.125 μg/mL，几何均数为0.10 μg/mL，MIC₅₀为0.125 μg/mL，MIC₉₀为0.125 μg/mL；对热带念珠菌的MIC范围为0.125~8.0 μg/mL，几何均数为0.57 μg/mL，MIC₅₀为0.5 μg/mL，MIC₉₀为2 μg/mL；对光滑念珠菌的MIC范围为0.06~2.0 μg/mL，几何均数为0.25 μg/mL，MIC₅₀为0.125 μg/mL，MIC₉₀为1 μg/mL；对克柔念珠菌的MIC范围为0.125~0.50 μg/mL，几何均数为0.29 μg/mL，MIC₅₀为0.25 μg/mL，MIC₉₀为0.5 μg/mL。结论对生殖器来源的氟康唑耐药白念珠菌及非白念珠菌，国产泊沙康唑均表现出了较好的体外抗菌活性，未来有望成为临床生殖器念珠菌病治疗的新选择。

关键词: 抗真菌药物, 泊沙康唑, 体外药物敏感性检测, 生殖器念珠菌病

Abstract: Objective To determine the in vitro antifungal activity of domestic posaconazole against the clinical isolates isolated from genital candidiasis. Methods We used the CLSI (Clinical and Laboratory Standards Institute) broth microdilution method M27-A4 to evaluate the minimal inhibitory concentration (MIC) of posaconazole and other common antifungal agents against 60 clinical isolates of Candida spp. Results The MIC range, geometric mean (GM), MIC₅₀ and MIC₉₀ of posaconazole against fluconazole-resistant C. albicans strain is 0.25-0.50 μg/mL, 0.40 μg/mL, 0.5 μg/mL and 0.5 μg/mL respectively. The data changed to 0.03-0.125 μg/mL, 0.10 μg/mL, 0.125 μg/mL and 0.125 μg/mL when posaconazole against C. parapsilosis. To C. tropicalis, the MIC range, GM, MIC₅₀ and MIC₉₀ is 0.125-8.0 μg/mL, 0.57 μg/mL, 0.5 μg/mL and 2 μg/mL respectively. To C. glabrata, the MIC range, GM, MIC₅₀ and MIC₉₀ is 0.06-2.0 μg/mL, 0.25 μg/mL, 0.125 μg/mL and 1 μg/mL respectively. And the MIC range and GM of posaconazole against C. krusei is 0.125-0.50 μg/mL and 0.29 μg/mL. The MIC₅₀ and MIC₉₀ of posaconazole against C. krusei is 0.25 μg/mL and 0.5 μg/mL, respectively. Conclusions Posaconazole is active against the fluconazole-resistant strains and non-albicans Candida strains associate with genital candidiasis.

Key words: antifungal agent, posaconazole, in vitro susceptibility tests, genital candidiasis

中图分类号:

R978.5

谭静文, 高志琴, 杨虹, 杨连娟. 国产泊沙康唑对生殖器来源念珠菌的体外药物敏感性研究[J]. 中国真菌学杂志, 2021, 16(5): 326-329,334.

TAN Jingwen, GAO Zhiqin, YANG Hong, YANG Lianjuan. In vitro antifungal activity of domestic posaconazole against pathogenic fungi isolated from genital candidiasis[J]. Chinese Journal of Mycology, 2021, 16(5): 326-329,334.

参考文献

[1] 王惠平.生殖器念珠菌病的诊治[J].中国临床医生, 2011, 39(2):11-13.
[2] 晏亮, 邓淑文, 潘炜华, 等.我国外阴阴道念珠菌病致病菌菌种分布及体外药敏研究现状[J].中国真菌学杂志, 2018, 13(1):46-52.
[3] Ge SH, Xie J, Xu J, et al. Prevalence of specific and phylogenetically closely related genotypes in the population of Candida albicans associated with genital candidiasis in China[J]. Fungal Genet Biol, 2012, 49(1):86-93.
[4] Li J, Fan SR, Liu XP, et al. Biased genotype distributions of Candida albicans strains associated with vulvovaginal candidosis and candidal balanoposthitis in China[J]. Clin Infect Dis, 2008, 47(9):1119-1125.
[5] 陈惠瑜, 邱华红, 方文婷, 等.773例女性外阴阴道念珠菌病菌种分布及药敏结果分析[J].实验与检验医学, 2020, 38(2):357-358, 368.
[6] Jeanmonod R, Jeanmonod D. Vaginal candidiasis (vulvovaginal candidiasis). StatPearls. Treasure Island (FL):StatPearls Publishing, 2021. https://pubmed.ncbi.nlm.nih.gov/29083806/
[7] Gonçalves B, Ferreira C, Alves CT, et al. Vulvovaginal candidiasis:Epidemiology, microbiology and risk factors[J]. Crit Rev Microbiol, 2016, 42(6):905-927.
[8] 中国成人念珠菌病诊断与治疗专家共识组.中国成人念珠菌病诊断与治疗专家共识[J].中国医学前沿杂志(电子版), 2020, 12(1):35-50.
[9] Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans Candida species in vulvovaginitis[J]. J Fungi (Basel), 2018, 4(4):121.
[10] Powell A, Ghanem KG, Rogers L, et al. Clinicians' use of intravaginal boric acid maintenance therapy for recurrent vulvovaginal candidiasis and bacterial vaginosis[J]. Sex Transm Dis, 2019, 46(12):810-812.
[11] 王东江(综述), 吴文娟(审校).外阴阴道念珠菌病研究进展[J].检验医学, 2016, 31(8):721-727.
[12] 刘飞飞, 王琴琴, 王玙, 等.口服氟康唑联合克霉唑栓治疗念珠菌性阴道炎临床疗效的meta分析[J].中国真菌学杂志, 2018, 13(5):257-261.
[13] CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI standard M27[S]. Wayne, PA:Clinical and Laboratory Standards Institute, 2017.
[14] CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts. 1st ed. CLSI supplement M60[S]. Wayne, PA:Clinical and Laboratory Standards Institute, 2017.
[15] Li Y, Theuretzbacher U, Clancy CJ, et al. Pharmacokinetic/pharmacodynamic profile of posaconazole[J]. Clin Pharmacokinet, 2010, 49(6):379-396.
[16] 泊沙康唑临床应用专家组.泊沙康唑临床应用专家共识[J].国际呼吸杂志, 2020, 40(4):241-261.
[17] 刘洁, 胡小平, 刘伟.三唑类抗真菌新药泊沙康唑和伏立康唑简介[J].菌物学报, 2018, 37(10):1391-1398.
[18] Song Y, Chen X, Yan Y, et al. Prevalence and antifungal susceptibility of pathogenic yeasts in China:A 10-year retrospective study in a teaching hospital[J]. Front Microbiol, 2020, 11:1401.
[19] Xiao M, Fan X, Chen SC, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China:3 year national surveillance[J]. J Antimicrob Chemother, 2015, 70(3):802-810.
[20] 王雪洁, 万哲, 李若瑜, 等.耐氟康唑念珠菌和耐伊曲康唑烟曲霉对泊沙康唑的敏感性测定[J].中国真菌学杂志, 2014, 9(2):75-78.
[21] González GM, Robledo E, Saldívar D, et al. Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model[J]. Med Mycol, 2007, 45(3):221-224.
[22] González GM, Elizondo M, Garza-González E, et al. Therapeutic efficacy of posaconazole against Candida glabrata in a murine model of vaginitis[J]. Mycoses, 2011, 54(2):119-122.
[23] Mendling W, Brasch J, Grman Society for Gynecology and Obstetrics, et al. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society[J]. Mycoses, 2012, 55(Suppl 3):1-13.